This website is intended for UK healthcare professionals only Log in | Register

Latest articles

January 2020 Br J Cardiol 2020;27(1) doi: 10.5837/bjc.2020.001 Online First

Cardiovascular complications of anti-cancer immune checkpoint inhibitor therapy and their combinations: are we ready for challenges ahead?

Alexandros Georgiou, Nadia Yousaf

Abstract

The use of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape for a number of tumour types over the past decade. Targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; ipilimumab), programmed cell death protein 1 (PD1; nivolumab, pembrolizumab), and programmed death-ligand 1 (PD-L1; atezolizumab, avelumab, or durvalumab), as monotherapy or in combination, activates the immune system to recognise and target cancer cells via a T-cell-mediated immune response and can lead to improved survival in the metastatic setting in a number of malignancies, as well as improved recurrence-free survival when utilised in multi-modality radical treatment paradigms in melanoma and non-small cell lung cancer (NSCLC).1,2 The systemic activation of T-cells can also lead to auto-immune toxicity, affecting any body system; most commonly skin, gastrointestinal, liver and endocrine toxicities.3

| Full text

January 2020 Br J Cardiol 2020;27(1) doi: 10.5837/bjc.2020.003 Online First

Cardiac tumours – a brief review

Amaliya A Arakelyanz, Tatiana E Morozova, Anna V Vlasova, Roman Lischke

Abstract

This short review of cardiac tumours presents a case that clearly demonstrates the manifestation of embolic and cardiac symptoms of an intracardiac mass. Acute onset and rapid progression of a neoplastic process in the heart leading to arrhythmia, cardiac conduction disorders and heart failure combined with highly mobile fragments of tumour, which can cause emboli in cerebral vessels, are characteristic signs of an intracardiac mass. Early diagnosis and immediate treatment may improve the long-term prognosis, but overall the prognosis is poor. Cardiac tumours present to the cardiologist when the patient presents with cardiac symptoms, and the neurologist when there are cerebral symptoms. Most cardiac masses are not amenable to percutaneous biopsy; therefore, definitive diagnosis often awaits surgical excision.

| Full text

January 2020 Br J Cardiol 2020;27(1) doi: 10.5837/bjc.2020.004 Online First

Successful treatment of ischaemic ventricular septal defect and acute right ventricular failure: a challenging case in the modern NHS

Renata Greco, Andrew Johnson, Xy Jin, Rajesh K Kharabanda, Adrian P Banning, Mario Petrou

Abstract

A 52-year-old man, previously fit and well, presented with myocardial infarction complicated by ischaemic ventricular septal defect (VSD) and acute right ventricular failure, was successfully treated with early percutaneous coronary reperfusion, surgical VSD repair and temporary right ventricular assist device (VAD) support.

This case is an example of how a modern healthcare system can successfully manage complex emergency cases, combining high levels of clinical care and medical technology. Access to temporary mechanical support played a vital role in this case. We believe that wider access to VADs may contribute to improvement in the, widely recognised, poor outcome of ischaemic VSD.

| Full text

November 2019 Br J Cardiol 2019;26:127

This issue – from the GP perspective

Terry McCormack

Abstract

When I first arrived at Whitby Group Practice (WGP) in the middle 80s, my surgery was next to Whitby Hospital Outpatients, where Anthony Bacon conducted his cardiology clinic. Dr Bacon’s article on aortic stenosis was in our previous issue.1 In this issue, Tariq Enezate and colleagues add to our knowledge of managing this condition.2

| Full text

November 2019 Br J Cardiol 2019;26:130–2 doi: 10.5837/bjc.2019.039

Depression screening in CAD may provide an opportunity to decrease health outcomes disparities

Adam Prince, Umair Ahmed, Nikhil Sharma, Rachel Bond

Abstract

Depressive symptoms in coronary artery disease (CAD) are known to associate with increased mortality. We evaluated management of depression screening in the outpatient setting for patients with known CAD at ambulatory visits. We assessed whether depression screening was performed with a patient health questionnaire, as well as what was done with positive results. Our study identified 355 patients who visited an ambulatory primary care clinic over a three-year period, 57% of whom were screened at least once. Positive scores for depression were found in 20% of patients screened, with 54% of screening-positive patients given plans for additional care. We found disparities between screening rates, with whites screened least for depression, as well as in management plans, with whites given highest probability of mentioned treatment in their assessment and plan if depression screening was positive. Given the association with increased mortality in known CAD, depression screening may represent an opportunity to decrease health outcomes disparities and to improve outcomes for patients with CAD in the outpatient setting.

| Full text
READ MORE

Latest news

MEETING REPORT Online First

Cardiorenal Forum 2019: integrating care in cardiorenal medicine

January 29, 2020

IN BRIEF

In briefs

November 29, 2019

MEETING REPORT

News from ESC 2019

October 9, 2019

MEETING REPORT

Updates from the American Diabetes Association 2019

September 3, 2019

MEETING REPORT

News from the BSH 21st Annual Autumn Meeting

September 3, 2019

IN BRIEF

In brief

September 3, 2019

READ MORE
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now